SELLAS Updates Phase 3 REGAL Trial in AML
NEW YORK, December 29, 2025 — SELLAS Life Sciences Group has provided a key update on its pivotal Phase...
Cancer Immunotherapy
Advertisement
CancerVax Marks 2025 Breakthroughs in Cancer Immunotherapy
LEHI, Utah — December 23, 2025 — CancerVax, a pre-clinical biopharmaceutical innovator, has released a year-end scientific and strategic...
Greenwich Reports 80% Recurrence Reduction in FLAMINGO-01
STAFFORD, Texas — December 15, 2025 — Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, announced a preliminary analysis from...
Phio Pharmaceuticals Advances siRNA Immunotherapy in Skin Cancer with INTASYL PH-762
Dateline — King of Prussia, Pennsylvania, November 7, 2025:Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has announced new clinical data from...
EU Approves KEYTRUDA for Resectable Head & Neck Cancer
Kenilworth, N.J., October 29, 2025— Merck & Co., Inc. (NYSE: MRK), known as MSD outside the U.S. and Canada,...
Advertisements
GemPharmatech Forms Oncology Collaboration to Boost Antibody Innovation
Nanjing, China – October 22, 2025 GemPharmatech Co., Ltd., a global leader in genetically engineered mouse models and preclinical...
Anixa Biosciences Completes Final Patient Visit in Breast Cancer Vaccine Trial
SAN JOSE, Calif., October 7, 2025 – Anixa Biosciences, Inc. (NASDAQ: ANIX), a clinical-stage biotechnology company dedicated to cancer...
Oncolytics Biotech Shows Favorable Safety for Pelareorep in GI Tumors
SAN DIEGO, Sept. 2, 2025 – Oncolytics Biotech® Inc. (Nasdaq: ONCY), a clinical-stage immunotherapy company, announced updated clinical safety...
Advertisement
